Globalpharma, a subsidiary of Dubai Investments Industries, the industry arm of Dubai Investments PJSC and the first pharmaceutical manufacturing company in Dubai that adheres to international quality standards, is to reinforce its commitment as a premier regional healthcare provider as it participates in DUPHAT 2008 – Dubai International Pharmaceuticals & Technologies Conference & Exhibition which will take place between March 10 – 12 at the Dubai International Exhibition Center.
“Recent reports have revealed that the Middle East is a rapidly growing market for medical products and services. As more and more expatriates move to the Gulf and Arab region, the need for first-rate healthcare has also exponentially grown. The UAE tops the list as the Middle Eastern country with the highest annual per capita consumption of medicines”, said Syed Jamil Akhtar, General Manager, Globalpharma.
“In light of this and in view of other challenges facing the pharmaceutical industry, DUPHAT is truly appreciated industry-wide as a leading unique regional platform that fosters mutual interaction between professionals, students and academics of pharmaceutical science. We are proud to be part of DUPHAT 2008.”
The three-day exhibition will witness Globalpharma unveil its latest products and present an overview on breakthrough products that are in the final stages of development and to be launched shortly. It will also showcase its advanced international standard manufacturing processes and present to attendees, major findings from its pharma and medical research undertaken over the last year.
“As part of its mission to be a premier healthcare company that constantly strives to deliver high-quality medicines that improve the quality of human life, Globalpharma is in the process of negotiating and finalizing deals with certain prominent research institutes and leading research-based pharmaceutical companies to acquire products with added value in the area of cardiovascular disease, aids, diabetes and oncology”, Akhtar added.
“Globalpharma has achieved an excellent 70 percent growth in 2007 and we look forward to emulating similar success in the coming year. While the task is challenging, we are confident that we will shortly be entering new markets such as South Africa and certain countries in the CIS region, launching between 7 – 8 new products in each major market.”
“We are also working towards obtaining approvals from international authorities such as the Medicines and Healthcare products Regulatory Agency, UK and the Food and Drug Authority (FDA), USA in coming months.
Established in 1998, Globalpharma manufactures and markets its own pharmaceutical products including antibiotics, cardiovascular, anti-ulcerants, analgesic NSAIDs, food supplements, vitamins, anti-diabetics, respiratory products in more than 20 countries of GCC, Middle East, Africa and Far east, in addition to marketing in license products from some other multinational pharmaceutical companies.
